MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Organogenesis Holdings Revenue 2011-2026 | ORGO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Organogenesis Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 482 M | 433 M | 451 M | 467 M | 338 M | 261 M | 193 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 482 M | 193 M | 375 M |
Quarterly Revenue Organogenesis Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151 M | 101 M | 86.7 M | - | 115 M | 130 M | 110 M | - | 109 M | 117 M | 108 M | - | 117 M | 121 M | 97.1 M | - | 114 M | 123 M | 103 M | - | 101 M | 69 M | 61.7 M | - | 64.3 M | 64.9 M | 57.1 M | 63.6 M | 50.8 M | 43.6 M | - | 53.1 M | 51.5 M | 54.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 151 M | 43.6 M | 90.2 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.29 | -0.6 % | $ 86.3 M |  Canada |
 |
China Pharma Holdings
CPHI
|
4.53 M | $ 0.63 | 0.3 % | $ 11 M |  China |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
46.7 M | $ 2.51 | -0.33 % | $ 1.31 B | Canada |
 |
DURECT Corporation
DRRX
|
8.55 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 7.98 | -0.87 % | $ 409 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 3.05 | - | $ 42.9 M | USA |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 4.99 | -2.35 % | $ 1.82 B | Canada |
 |
Harrow Health
HROW
|
272 M | $ 34.02 | 0.05 % | $ 1.25 B | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
Evolus
EOLS
|
297 M | $ 4.54 | -3.1 % | $ 293 M | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 22.49 | -0.71 % | $ 1.04 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 5.8 | -1.02 % | $ 229 M | USA |
 |
Rockwell Medical
RMTI
|
83.6 M | $ 1.03 | 0.98 % | $ 24 M | USA |
 |
Assertio Holdings
ASRT
|
119 M | $ 14.91 | 6.5 % | $ 95.5 M | USA |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 0.95 | -2.29 % | $ 102 M | Canada |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.35 | -0.74 % | $ 402 M | Canada |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.35 | -1.1 % | $ 3.37 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 2.42 | -5.1 % | $ 3 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
123 M | - | - | $ 5.07 M | USA |
 |
Jupiter Wellness
JUPW
|
702 K | - | - | $ 33.6 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
627 M | $ 6.41 | -0.7 % | $ 3.96 B | Canada |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 0.9 | 3.23 % | $ 44.9 M | USA |
 |
TherapeuticsMD
TXMD
|
1.3 M | $ 2.31 | - | $ 24.1 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
Viatris
VTRS
|
15.4 B | $ 13.2 | -0.68 % | $ 15.8 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
25 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
4.25 B | $ 9.43 | -1.46 % | $ 1.31 B | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 0.76 | -1.19 % | $ 3.28 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |